In conclusion, there remains a multi-faceted exploration ahead to enhance the treatment effects of FAP-targeted RLT, determining the optimal choice between beta-emitter and alpha-emitter radionuclides, considering shorter half-life radionuclides and exploring combination treatments with therapies directly targeting tumor cells. This evidence concerns the gene FAP and neoplasm.